On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Subscribe To Our Newsletter & Stay Updated
